Geode Capital Management LLC cut its stake in shares of Genomic Health (NASDAQ:GHDX) by 14.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 179,465 shares of the medical research company’s stock after selling 31,536 shares during the period. Geode Capital Management LLC owned approximately 0.52% of Genomic Health worth $6,137,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. grew its stake in Genomic Health by 1.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 503,244 shares of the medical research company’s stock valued at $16,150,000 after acquiring an additional 5,904 shares during the period. American Century Companies Inc. grew its stake in Genomic Health by 9.1% in the fourth quarter. American Century Companies Inc. now owns 194,503 shares of the medical research company’s stock valued at $6,652,000 after acquiring an additional 16,217 shares during the period. First Manhattan Co. grew its stake in Genomic Health by 58.4% in the fourth quarter. First Manhattan Co. now owns 110,900 shares of the medical research company’s stock valued at $3,792,000 after acquiring an additional 40,900 shares during the period. Citadel Advisors LLC grew its stake in Genomic Health by 5.5% in the fourth quarter. Citadel Advisors LLC now owns 98,933 shares of the medical research company’s stock valued at $3,384,000 after acquiring an additional 5,130 shares during the period. Finally, Wells Fargo & Company MN grew its stake in Genomic Health by 26.8% in the fourth quarter. Wells Fargo & Company MN now owns 87,325 shares of the medical research company’s stock valued at $2,987,000 after acquiring an additional 18,441 shares during the period. 89.99% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

GHDX stock opened at $33.31 on Tuesday. The stock has a market cap of $1,166.41, a PE ratio of 3,331.00 and a beta of 0.63. Genomic Health has a fifty-two week low of $26.54 and a fifty-two week high of $37.50.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Thursday, March 8th. The medical research company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $87.50 million for the quarter, compared to analyst estimates of $88.96 million. Genomic Health had a negative return on equity of 0.83% and a negative net margin of 1.13%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.04 earnings per share. research analysts anticipate that Genomic Health will post 0.43 EPS for the current fiscal year.

A number of research analysts have issued reports on the company. ValuEngine cut Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Piper Jaffray reissued a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a research note on Thursday, March 8th. BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. William Blair cut Genomic Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Finally, Zacks Investment Research cut Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company. Genomic Health presently has a consensus rating of “Hold” and an average price target of $32.67.

In other news, insider Phillip G. Febbo sold 4,942 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $32.84, for a total transaction of $162,295.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kimberly J. Popovits sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $32.93, for a total value of $329,300.00. The disclosure for this sale can be found here. Insiders have sold 24,942 shares of company stock valued at $820,045 over the last ninety days. 46.20% of the stock is owned by insiders.

WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/04/17/geode-capital-management-llc-has-6-14-million-position-in-genomic-health-ghdx.html.

Genomic Health Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.